From L-R: Zavain Dar, Adam Goulburn and Nan Li (Dimension)
January 25, 2023 07:00 AM EST
Financing
Startups

‘Silo­ing is just so out­dat­ed’: New $350M VC fund aims to dig­i­tize life sci­ences

Kyle LaHucik

Senior Reporter

As tech­nol­o­gy in­creas­ing­ly helps find drug tar­gets, en­hance the di­ag­no­sis of dis­eases, speed up the test­ing of new ther­a­peu­tics and es­sen­tial­ly an­gle its way in­to every cor­ner of life sci­ences, en­tre­pre­neurs will need a new type of VC firm.

At least, that’s the think­ing be­hind the lat­est fund to drop. Di­men­sion, out of New York and San Fran­cis­co, launched Wednes­day with $350 mil­lion to bankroll a cou­ple dozen star­tups, some of which it will help form. The port­fo­lio al­ready in­cludes Kalei­do­scope, mak­er of a tool to help teams keep tabs on R&D, and Enve­da Bio­sciences, which is near­ing the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

A service from the Financial Times